Seres Therapeutics (MCRB) Income towards Parent Company (2016 - 2024)
Historic Income towards Parent Company for Seres Therapeutics (MCRB) over the last 10 years, with Q3 2024 value amounting to $139.8 million.
- Seres Therapeutics' Income towards Parent Company rose 214431.93% to $139.8 million in Q3 2024 from the same period last year, while for Jun 2025 it was $139.8 million, marking a year-over-year increase of 61261.64%. This contributed to the annual value of $125.9 million for FY2024, which is 6478.68% up from last year.
- According to the latest figures from Q3 2024, Seres Therapeutics' Income towards Parent Company is $139.8 million, which was up 214431.93% from -$6.7 million recorded in Q2 2024.
- In the past 5 years, Seres Therapeutics' Income towards Parent Company ranged from a high of $139.8 million in Q3 2024 and a low of -$71.5 million during Q1 2023
- In the last 5 years, Seres Therapeutics' Income towards Parent Company had a median value of -$20.2 million in 2020 and averaged -$13.1 million.
- Its Income towards Parent Company has fluctuated over the past 5 years, first tumbled by 19726.9% in 2023, then surged by 214431.93% in 2024.
- Over the past 5 years, Seres Therapeutics' Income towards Parent Company (Quarter) stood at -$18.0 million in 2020, then crashed by 175.35% to -$49.7 million in 2021, then skyrocketed by 95.58% to -$2.2 million in 2022, then tumbled by 197.27% to -$6.5 million in 2023, then soared by 2240.73% to $139.8 million in 2024.
- Its last three reported values are $139.8 million in Q3 2024, -$6.7 million for Q2 2024, and -$7.2 million during Q1 2024.